Investors are starting to forecast a post-pandemic world. As part of these efforts, it is crucial that they understand and manage the risks of antimicrobial resistance (AMR). If left unchecked, AMR is set to substantially undermine the global economy’s financial recovery and future outlook. Here, we run through the main risks and opportunities presented by superbugs for pharma companies and resources available for navigating through them.
By Mara Lilley, Investor Engagement Manager and Sana Johnson, Strategy Research Assistant